Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CETP | P11597 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.32 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4290542 | 1.00 | LMNA (0.44) | LMNAL3MBTL1TDP1ALDH1A1CETP | |
| SCHEMBL3970934 | 1.00 | LMNA (0.44) | LMNAL3MBTL1TDP1ALDH1A1CETP | |
| SCHEMBL4076760 | 1.00 | LMNA (0.44) | LMNAL3MBTL1TDP1ALDH1A1CETP | |
| Hydrochloric Acid SCHEMBL3675135 | 0.96 | LMNA (0.41) | LMNAL3MBTL1TDP1ALDH1A1CETP | |
| Hydrochloric Acid SCHEMBL3670637 | 0.96 | LMNA (0.41) | LMNAL3MBTL1TDP1ALDH1A1CETP | |
| SCHEMBL5697239 | 0.92 | LMNA (0.35) | LMNAL3MBTL1TDP1ALDH1A1CETP | |
| SCHEMBL18532443 | 0.92 | LMNA (0.35) | LMNAL3MBTL1TDP1ALDH1A1CETP | |
| Hydrochloric Acid SCHEMBL3672161 | 0.88 | LMNA (0.33) | LMNAL3MBTL1TDP1ALDH1A1CETP | |
| Hydrochloric Acid SCHEMBL3672162 | 0.88 | LMNA (0.33) | LMNAL3MBTL1TDP1ALDH1A1CETP | |
| SCHEMBL24398891 | 0.87 | LMNA (0.69) | LMNAL3MBTL1TDP1ALDH1A1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9907854-B2 | Crosslinking reagents, macromolecules, therapeutic bioconjugates, and synthetic methods thereof | CellMosaic, Inc. (US) | 2018-03-06 | — | — | US | disclosed |
| US-9907854-B2 | Crosslinking reagents, macromolecules, therapeutic bioconjugates, and synthetic methods thereof | CellMosaic, Inc. (US) | 2018-03-06 | — | — | US | disclosed |
| US-20170065726-A1 | NOVEL CROSSLINKING REAGENTS, MACROMOLECULES, THERAPEUTIC BIOCONJUGATES, AND SYNTHETIC METHODS THEREOF | CELLMOSAIC INC (US) | 2017-03-09 | — | — | US | disclosed |
| US-20170065726-A1 | NOVEL CROSSLINKING REAGENTS, MACROMOLECULES, THERAPEUTIC BIOCONJUGATES, AND SYNTHETIC METHODS THEREOF | CELLMOSAIC INC (US) | 2017-03-09 | — | — | US | disclosed |
| US-9511150-B2 | Crosslinking reagents, macromolecules, therapeutic bioconjugates, and synthetic methods thereof | CellMosaic, Inc. (US) | 2016-12-06 | — | — | US | disclosed |
| US-8907079-B2 | Crosslinking reagents, macromolecules, therapeutic conjugates, and synthetic methods thereof | CELLMOSAIC INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20140206903-A1 | NOVELCROSSLINKING REAGENTS, MACROMOLECULES, THERAPEUTIC CONJUGATES, AND SYNTHETIC METHODS THEREOF | CELLMOSAIC INC (US) | 2014-07-24 | — | — | US | disclosed |
| WO-2013012961-A2 | NOVEL CROSSLINKING REAGENTS, MACROMOLECULES, THERAPEUTIC CONJUGATES, AND SYNTHETIC METHODS THEREOF | CELLMOSAIC, LLC (US) | 2013-01-24 | — | — | WO | disclosed |
| US-20090098145-A1 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | SIRION THERAPEUTICS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090098145-A1 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | SIRION THERAPEUTICS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| EP-0558732-B1 | PRODUCTION OF CHROMOSOME REGION SPECIFIC DNA SEQUENCES AND TRANSAMINATION | AMOCO CORP (US) | 1999-03-03 | — | — | EP | disclosed |
| EP-0558740-B1 | PROBE COMPOSITION FOR GENOME IDENTIFICATION AND METHODS | VYSIS INC (US) | 1998-08-05 | — | — | EP | disclosed |
| US-5789161-A | Methods for genome identification using direct label probe composition | AMOCO CORPORATION (US) | 1998-08-04 | — | — | US | disclosed |
| US-5776688-A | Methods for detection by in situ hybridization of multiple chromosomes or regions thereof | VYSIS, INC. (US) | 1998-07-07 | — | — | US | disclosed |
| US-5663319-A | Probe compositions for chromosome identification and methods | VYSIS, INC. (US) | 1997-09-02 | — | — | US | disclosed |
| EP-0787805-A2 | Probe compositions for chromosome identification and method | AMOCO CORPORATION (US) | 1997-08-06 | — | — | EP | disclosed |
| EP-0549709-B1 | PROBE COMPOSITIONS FOR CHROMOSOME IDENTIFICATION AND METHODS | AMOCO CORP (US) | 1997-01-29 | — | — | EP | disclosed |
| US-5506350-A | IN PRESENCE OF A TRIFLUOROACETATE CHAOTROPE | BITTNER MICHAEL L (US) | 1996-04-09 | — | — | US | disclosed |
| US-5491224-A | FOR IN SITU HYBRIDIZATION ENUMERATIONS OF SPECIFIC CHROMOSOME CENTROMERES | VYSIS, INC. | 1996-02-13 | — | — | US | disclosed |
| US-4237273-A | ANTITUMOR AGENTS; LEUKEMIA | RICHTER GEDEON VEGYESZETI GYAR RT (HU) | 1980-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170065726-A1 | NOVEL CROSSLINKING REAGENTS, MACROMOLECULES, THERAPEUTIC BIOCONJUGATES, AND SYNTHETIC METHODS THEREOF | CD44, ADH1C, EPCAM | LMNA 4262/4885L3MBTL1 2520/4885TDP1 4207/4885 |
| US-20090098145-A1 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | ALDH1A2, PDE6C, EYA2 | LMNA 402/4885L3MBTL1 3794/4885TDP1 1770/4885 |
| US-20140206903-A1 | NOVELCROSSLINKING REAGENTS, MACROMOLECULES, THERAPEUTIC CONJUGATES, AND SYNTHETIC METHODS THEREOF | CD44, ADH1C, EPCAM | LMNA 4454/4885L3MBTL1 2862/4885TDP1 4314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.